Vimarsana
Biggest News Aggregation in the World

Page 3 - Simon Crabb News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Simon Crabb. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Simon Crabb Today - Breaking & Trending Today

Investegate |Prime People PLC Announcements | Prime People PLC: Proposed Cancellation and Tender Offer - Vimarsana News

Investegate |Prime People PLC Announcements | Prime People PLC: Proposed Cancellation and Tender Offer

Investegate announcements from Prime People PLC, Proposed Cancellation and Tender Offer

Timothy Jobling, 74, died after chemotherapy to treat prostate cancer - Vimarsana News

Timothy Jobling, 74, died after chemotherapy to treat prostate cancer

A DEVOTED charity trustee who "knew everyone in Winchester and Southampton" died after undergoing chemotherapy to treat prostate cancer.

Timothy Jobling, 74, died after chemotherapy to treat prostate cancer - Vimarsana News

Timothy Jobling, 74, died after chemotherapy to treat prostate cancer

A DEVOTED charity trustee who "knew everyone in Winchester and Southampton" died after undergoing chemotherapy to treat prostate cancer.

Southampton to help spearhead bladder cancer trial - Vimarsana News

Southampton to help spearhead bladder cancer trial

Dr Simon Crabb SOUTHAMPTON is to help spearhead an international trial which will look to help improve the lives of bladder cancer patients. The first UK patients have now been recruited to take part in tests looking at whether an immunotherapy treatment could improve the long-term outcomes following radiotherapy for those suffering from the disease. Named the BL-13 trial, it is being led by Dr Simon Crabb at the CRUK Southampton Clinical Trials Unit, based within the University of Southampton’s Centre for Cancer Immunology. Around 10,000 people are diagnosed with bladder cancer each ...

BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma - Vimarsana News

BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

Search jobs 14-Dec-2020 BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma Feltham (Merck) & Walton Oaks (Pfizer) – Merck and Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of BAVENCIO ® (avelumab) as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinom...